|
|
|
| Effects of Different Doses of Mifepristone on Sex Hormone Levels in Patients with Uterine Fibroid and Anemia |
| DONG Lijun, WANG Wei |
| Department of Gynecology,Pucheng County Hospital,Weinan Shaanxi 715500 |
|
|
|
|
Abstract 【Objective】To investigate the effect of different doses of mifepristone on sex hormone levels in patients with Uterine fibroid and anemia.【Methods】From March 2019 to March 2021,90 patients with Uterine fibroid and anemia in the Pucheng County Hospital were selected and divided into observation group and control group according to random number table,with 45 cases in each group. The control group received high-dose mifepristone (20 mg/dose) treatment before surgery,while the observation group received low-dose mifepristone (10 mg/dose) treatment before surgery. The operation time,intraoperative blood loss,hospital stay,hemoglobin content 24 hours after operation,adverse reactions after medication,levels of sex hormones [luteinizing hormone (LH),progesterone (P),Follicle-stimulating hormone (FSH),estradiol (E2)],diameter of Uterine fibroid,uterine volume,and quality of life scale (QOL) scores were compared between the two groups.【Results】There was no statistically significant difference (P>0.05) between the two groups in terms of surgical time,intraoperative bleeding volume,length of hospital stay,and postoperative 24 hour hemoglobin levels; The levels of LH,P,FSH,and E2 in the two groups of patients after treatment were lower than those in the same group before treatment,and the difference was statistically significant (P<0.05); After treatment,the diameter of fibroids and uterine volume of the two groups of patients were smaller than that before treatment,and the QOL scores was higher than that before treatment,with a statistically significant difference (P<0.05); The incidence of adverse reactions after medication in the observation group (15.56%) was significantly lower than that in the control group (35.56%),with a statistically significant difference (P<0.05).【Conclusion】Preoperative use of low-dose mifepristone in patients with Uterine fibroid and anemia can effectively reduce the level of sex hormones,reduce the volume of leiomyoma,and has high safety.
|
|
Received: 21 September 2022
|
|
|
|
|
|
[1] 王丽燕,罗宇迪,王兴红. 子宫肌瘤合并月经过多的危险因素分析及风险预测模型构建[J].中国计划生育和妇产科,2021,13(3):43-47.
[2] 徐书峰. 子宫肌瘤的介入治疗进展[J].实用放射学杂志,2020,36(6):998-1000.
[3] 张定红,王宏丽.不同剂量米非司酮治疗子宫肌瘤的临床疗效比较[J].中国计划生育学杂志,2020,28(11):1821-1823.
[4] 华芬芬,严礼平.子宫肌瘤与正常子宫肌层中14-3-3γ蛋白的表达及与雌、孕激素受体、临床病理参数相关性研究[J].中国性科学,2020,29(11):91-95.
[5] 武群英,王晓誉.米非司酮不同配伍方式用于瘢痕子宫中期妊娠引产的疗效及安全性比较[J].医学临床研究,2021,38(10):1493-1496.
[6] 苗华艳. 现代子宫肌瘤诊断与治疗[M]. 长春:吉林科学技术出版社,2011:103-104.
[7] SDERSTRM L,BERGKVIST L,ROSENBLAD A. Oral nutritional supplement use is weakly associated with increased subjective health-related quality of life in malnourished older adults: a multicentre randomised controlled trial[J].Br J Nutr,2022,127(1):103-111.
[8] SHIKHA S,NEERU G,EKTA S,et al. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman[J].J Mid-life Health,2020,4(1):22-26.
[9] 郑雨,戴秋香,梁菊,等.米非司酮联合桂枝茯苓胶囊对子宫肌瘤患者血清雌、孕激素及氧化应激因子水平的影响[J].医学临床研究,2020,37(7):1008-1010.
[10] 卞美璐,黄敏丽,张震宇,等.低剂量米非司酮用于子宫肌瘤的术前治疗多中心随机双盲、安慰剂、平行对照研究[J].中华妇产科杂志,2021,56(5):317-327.
[11] CARBONELL J,ACOSTA R,MARRERO AG,et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial[J].Int J Women's Health,2013,19(5):115-124.
[12] 封全灵,熊祯祯,王智霆,等. 米非司酮对孕激素受体M阳性子宫肌瘤细胞增殖、凋亡的影响[J].山东医药,2017,57(3):13-15.
[13] 刘瑞莲. 不同剂量米非司酮治疗子宫肌瘤的临床探讨[J].中外医疗,2016,35(7):123-124.
[14] 张志恒,谢卓,陈娟.曲普瑞林联合不同剂量米非司酮在子宫肌瘤治疗中的应用价值研究[J].中国性科学,2021,30(2):85-88.
[15] 李海艳,唐晓慧. 米非司酮不同剂量用药方案对子宫肌瘤的疗效及安全性分析[J].沈阳药科大学学报,2021,38(1):66. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(8): 1247-1249. |
|
|
|
|
2023, Vol. 40 
